ROME (ITALPRESS) – In relation to press reports on the clinical trial of a potential long-coverage vaccine model against Sars-Cov2 at the Istituto Superiore di Sanita ‘, the ISS specifies that “this model is currently being preclinical study, on animal models, and this phase has not yet been completed. The research has not been stopped but is following the normal consolidation process as for all other potential vaccine models. The possible long duration of vaccination coverage obviously is not is still supported by scientific evidence but is based on literature data and in the course of development, the need for integration with current vaccine technologies (mRNA vaccines) is not excluded. make a quantitative estimate of the effectiveness and effective duration of vaccination coverage “. “The technology of the ISS vaccine, currently under study, is based on the activation of immunity induced by CD8 T cells, it is original compared to the others in use and further possible developments are being studied – continues the note -. L ‘In recognizing the potential of research, the Institute has systematically supported the requests for funding necessary for its development and has also deemed it appropriate to protect it by filing an additional patent application to possibly guarantee its use for the protection of public health “. (ITALPRESS). fsc / com 13-May-21 16:02
COPYRIGHT today © breaking latest news